Streetbeat News

Regulatory

MFG

MUFG

SMFG

Shares of US-listed Japanese banks are trading lower due to flat BoJ Core CPI data. BoJ Governor Kazuo Ueda indicated potential rate hikes if inflation targets are met.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 2:51 pm

EWJ

X

The United Steelworkers (USW) strongly opposes the arbitration decision regarding the merger between U.S. Steel and Nippon Steel, citing potential threats to jobs and domestic steelmaking capacity. The Committee on Foreign Investment in the United States (CFIUS) approval is still pending due to national security concerns.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 2:45 pm

FXI

SPY

The U.S. National Security Council (NSC) spokesperson announced that the U.S. is ready to take immediate action against Chinese companies named in a report for their involvement with a sanctioned Russian entity. The U.S. will also investigate banks that facilitated these transactions.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:49 pm

SUI

Soren Aandahl of Blue Orca Capital presented a short thesis on Sun Communities, alleging conflicts of interest and dubious executive behavior. The firm claims that Sun Communities manipulates financial disclosures to inflate adjusted funds from operation and organic growth.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:48 pm

NNDM

Trading for a certain asset was halted at 9:40:28 a.m. ET due to pending news. This indicates that significant information is expected to be released, which could impact the asset's price once trading resumes.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:40 pm

FLUT

Flutter's CEO discussed the company's 2027 U.S. profit growth projections, which are based on the current regulatory environment. The company is prepared to adjust to tax changes and is open to acquisitions in the U.S. and globally.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:36 pm

CERO

CERo Therapeutics shares rose following the announcement of $1.25 million in financing and a request for an FDA type A meeting to address the clinical hold on CER-1236.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2024 | 1:36 pm

HRTS

NVO

Novo Nordisk is facing political pressure over high U.S. prices for its weight-loss drugs, Ozempic and Wegovy, as the U.S. presidential election approaches. The company's CEO testified before Congress, attributing pricing issues to pharmacy benefit managers (PBMs). Despite potential price cuts, demand for these drugs remains strong, and Novo Nordisk's U.S. revenues are expected to remain stable. The political focus on drug pricing is bipartisan, and increased M&A activity in the pharmaceutical sector is anticipated post-election.

Portfolio Pulse from Piero Cingari

September 25, 2024 | 1:35 pm